Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by Arrakis37on Jul 29, 2020 7:50pm
92 Views
Post# 31340736

RE:dont ask me where i got this, it's a secret (q3 baby)

RE:dont ask me where i got this, it's a secret (q3 baby)On March 28, 2018, the name of the company was Prometic Life Science.

Another distorsion of reality made in Thomvest.

LOL

Genius.

Newcamo wrote:

On March 28, 2018, Liminal BioSciences provided an update on the status of the FDA review of its BLA for Ryplazim®, and subsequently the FDA issued a Complete Response Letter (“CRL”). The FDA identified the need for Liminal BioSciences to make a number of changes in the Chemistry Manufacturing and Controls (“CMC”) section. These require the implementation and validation of additional analytical assays and “in-process controls” in the manufacturing process of Ryplazim®. Once completed and validated, Liminal BioSciences is required to manufacture additional Ryplazim® conformance batches to confirm the effectiveness of these process changes.

The FDA has indicated that the submission of the amended BLA for Ryplazim® will not impact the previously granted designations, including the Priority Review Status, the Orphan Drug Designation and the Rare Pediatric Disease Designation for Ryplazim® for the treatment of PLDG.

The Company expects to be filing an amendment to the BLA in Q3 2020 .




<< Previous
Bullboard Posts
Next >>